SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.3 CNY | -0.81% |
|
-3.92% | +3.51% |
| Apr. 25 | Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023 | MT |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.81 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.51% | 2.01B | - | ||
| -3.07% | 90.45B | A- | ||
| +3.95% | 41.45B | A- | ||
| -10.51% | 33.57B | B- | ||
| +60.58% | 25.73B | A | ||
| -20.09% | 14.73B | C | ||
| -8.92% | 12.82B | B- | ||
| -11.46% | 11.7B | D+ | ||
| -43.05% | 11.44B | B | ||
| +5.17% | 8.79B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- 688336 Stock
- Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
